Biomerica, Inc.(BMRA)Earnings, Financials & Key Ratios
BMRA•NASDAQ
$2.20
$6M mkt cap·Price updated May 7, 2026
AboutBiomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Show more
- Revenue$5M-1.9%
- EBITDA-$5M+21.0%
- Net Income-$5M+16.8%
- EPS (Diluted)-2.16-500.0%
- Gross Margin9.38%-16.9%
- EBITDA Margin-89.19%+19.4%
- Operating Margin-96.72%+17.7%
- Net Margin-93.64%+15.2%
- ROE-92.99%-42.4%
- ROIC-143.49%+5.5%
- Debt/Equity0.11-6.3%
BMRA Key Insights
Biomerica, Inc. (BMRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 86.3% through buybacks
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BMRA Price & Volume
Biomerica, Inc. (BMRA) stock price & volume — 10-year historical chart
Loading chart...
BMRA Growth Metrics
Biomerica, Inc. (BMRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years0.68%
5 Years-4.52%
3 Years-34.47%
TTM-20.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM28.19%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-105.64%
Return on Capital
10 Years-47.61%
5 Years-65.02%
3 Years-74.15%
Last Year-91.28%
BMRA Peer Comparison
Biomerica, Inc. (BMRA) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CODX | 2.15M | 1.93 | -0.05 | -84.1% | -75.34% | -125.46% | 0.06 | |
 QDEL | 733.24M | 10.77 | -0.65 | -1.89% | -45.57% | -56.31% | 1.46 | |
 OSUR | 225.25M | 3.13 | -3.33 | -38.1% | -61.93% | -15.09% | 0.04 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 BIO | 6.95B | 257.32 | 9.23 | 0.65% | 6.52% | 2.4% | 0.21 | |
 NEOG | 2.01B | 9.25 | -1.84 | -3.2% | -68.47% | -28.64% | 0.44 | |
 IDXX | 45.45B | 572.20 | 43.75 | 10.42% | 24.63% | 70.87% | 0.67 | |
 CHEK | 12.17M | 2.08 | -0.48 | -226.19% |
Compare BMRA vs Peers
Biomerica, Inc. (BMRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BMRA Income Statement
Biomerica, Inc. (BMRA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | May'17 | May'18 | May'19 | May'20 | May'21 | May'22 | May'23 | May'24 | May'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.79M | 5.56M | 5.2M | 6.69M | 7.2M | 18.87M | 5.34M | 5.42M | 5.31M | 4.46M |
| Revenue Growth % | 12.68% | -3.93% | -6.53% | 28.69% | 7.57% | 162.14% | -71.71% | 1.42% | -1.92% | -20.05% |
| Cost of Goods Sold | 3.77M | 3.81M | 3.91M | 4.91M | 6.83M | 15.89M | 4.89M | 4.8M | 4.81M | 4.21M |
| COGS % of Revenue | 65.09% | 68.47% | 75.16% | 73.38% | 94.91% | 84.22% | 91.65% | 88.72% | 90.62% | - |
| Gross Profit | 2.02M▲ 0% | 1.75M▼ 13.2% | 1.29M▼ 26.4% | 1.78M▲ 37.9% | 366.29K▼ 79.4% | 2.98M▲ 712.9% | 446K▼ 85.0% | 611K▲ 37.0% | 498K▼ 18.5% | 250K▲ 0% |
| Gross Margin % | 34.91% | 31.53% | 24.84% | 26.62% | 5.09% | 15.78% | 8.35% | 11.28% | 9.38% | 5.61% |
| Gross Profit Growth % | 32.66% | -13.23% | -26.36% | 37.91% | -79.44% | 712.87% | -85.02% | 37% | -18.49% | - |
| Operating Expenses | 2.98M | 3.24M | 3.7M | 4.18M | 7.87M | 7.51M | 7.67M | 6.98M | 5.63M | 5.51M |
| OpEx % of Revenue | 51.39% | 58.16% | 71.24% | 62.53% | 109.26% | 39.8% | 143.64% | 128.86% | 106.1% | - |
| Selling, General & Admin | 1.85M | 1.84M | 2.03M | 2.27M | 5.67M | 5.7M | 6.08M | 5.49M | 4.61M | 4.64M |
| SG&A % of Revenue | 31.87% | 33.03% | 38.95% | 33.98% | 78.78% | 30.2% | 113.97% | 101.33% | 86.84% | - |
| Research & Development | 1.13M | 1.4M | 1.68M | 1.91M | 2.19M | 1.81M | 1.58M | 1.49M | 1.02M | 874K |
| R&D % of Revenue | 19.52% | 25.13% | 32.29% | 28.54% | 30.48% | 9.6% | 29.67% | 27.53% | 19.26% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 0 | 0 | 0 |
| Operating Income | -954.63K▲ 0% | -1.48M▼ 55.2% | -2.41M▼ 62.8% | -2.4M▲ 0.4% | -7.5M▼ 212.1% | -4.53M▲ 39.5% | -7.22M▼ 59.3% | -6.37M▲ 11.9% | -5.14M▲ 19.3% | -5.26M▲ 0% |
| Operating Margin % | -16.48% | -26.63% | -46.39% | -35.9% | -104.18% | -24.03% | -135.29% | -117.58% | -96.72% | -118.1% |
| Operating Income Growth % | -15.44% | -55.22% | -62.83% | 0.41% | -212.12% | 39.54% | -59.31% | 11.85% | 19.32% | - |
| EBITDA | -735.41K | -1.3M | -2.25M | -2M | -7.12M | -3.94M | -6.87M | -5.99M | -4.74M | -4.86M |
| EBITDA Margin % | -12.7% | -23.28% | -43.26% | -29.95% | -98.96% | -20.87% | -128.71% | -110.67% | -89.19% | -108.95% |
| EBITDA Growth % | -23.7% | -76.11% | -73.72% | 10.92% | -255.44% | 44.7% | -74.45% | 12.79% | 20.96% | 13.28% |
| D&A (Non-Cash Add-back) | 219.22K | 186.6K | 162.91K | 398.63K | 375.86K | 594.82K | 351K | 374K | 400K | 408K |
| EBIT | -908.28K | -1.43M | -2.37M | -2.33M | -7.43M | -4.53M | -7.22M | -6.37M | -5.14M | -4.08M |
| Net Interest Income | 46.07K | 47.73K | 43.97K | 71.18K | 66.5K | 27K | 133K | 431K | 165K | 1.25M |
| Interest Income | 46.35K | 47.76K | 44.01K | 71.19K | 66.86K | 27K | 133K | 431K | 165K | 1.25M |
| Interest Expense | 282 | 37 | 47 | 9 | 367 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 46.07K | 47.73K | 43.97K | 71.18K | 66.5K | 26.64K | 134K | 431K | 165K | 1.25M |
| Pretax Income | -908.56K▲ 0% | -1.43M▼ 57.8% | -2.37M▼ 65.2% | -2.33M▲ 1.6% | -7.43M▼ 218.8% | -4.51M▲ 39.4% | -7.09M▼ 57.3% | -5.94M▲ 16.3% | -4.97M▲ 16.2% | -4.02M▲ 0% |
| Pretax Margin % | -15.69% | -25.77% | -45.55% | -34.84% | -103.25% | -23.88% | -132.78% | -109.62% | -93.62% | -90.09% |
| Income Tax | 0 | 31.8K | 24.24K | 7.39K | 13.06K | 23.72K | 51K | 42K | 1K | 9K |
| Effective Tax Rate % | 0% | -2.22% | -1.02% | -0.32% | -0.18% | -0.53% | -0.72% | -0.71% | -0.02% | -0.22% |
| Net Income | -908.56K▲ 0% | -1.47M▼ 61.3% | -2.39M▼ 63.3% | -2.34M▲ 2.3% | -7.45M▼ 218.3% | -4.53M▲ 39.2% | -7.14M▼ 57.6% | -5.98M▲ 16.3% | -4.97M▲ 16.8% | -4.03M▲ 0% |
| Net Margin % | -15.69% | -26.34% | -46.01% | -34.95% | -103.43% | -24.01% | -133.73% | -110.4% | -93.64% | -90.29% |
| Net Income Growth % | 39.42% | -61.34% | -63.26% | 2.26% | -218.34% | 39.15% | -57.58% | 16.27% | 16.81% | 28.19% |
| Net Income (Continuing) | -908.56K | -1.47M | -2.39M | -2.34M | -7.45M | -4.53M | -7.14M | -5.98M | -4.97M | -4.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.11▲ 0% | -0.17▼ 54.5% | -0.26▼ 52.9% | -0.23▲ 11.5% | -0.54▼ 134.8% | -0.36▲ 33.3% | -0.50▼ 38.9% | -0.36▲ 28.0% | -2.16▼ 500.0% | -1.38▲ 0% |
| EPS Growth % | 45% | -54.55% | -52.94% | 11.54% | -134.78% | 33.33% | -38.89% | 28% | -500% | -105.64% |
| EPS (Basic) | -0.11 | -0.17 | -0.26 | -0.23 | -0.54 | -0.36 | -0.50 | -0.36 | -2.16 | - |
| Diluted Shares Outstanding | 8.33M | 8.57M | 9.21M | 10.17M | 11.93M | 12.67M | 14.15M | 16.82M | 2.3M | 2.91M |
| Basic Shares Outstanding | 8.26M | 8.57M | 9.21M | 10.17M | 11.93M | 12.67M | 14.15M | 16.82M | 2.3M | 2.91M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BMRA Balance Sheet
Biomerica, Inc. (BMRA) balance sheet — assets, liabilities & shareholders' equity
| Line item | May'17 | May'18 | May'19 | May'20 | May'21 | May'22 | May'23 | May'24 | May'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.21M | 4.48M | 4.49M | 14.77M | 9.23M | 9.43M | 12.8M | 7.73M | 4.88M | 5.19M |
| Cash & Short-Term Investments | 1.23M | 1.2M | 686.78K | 8.64M | 4.2M | 5.92M | 9.72M | 4.17M | 2.4M | 2.54M |
| Cash Only | 1.23M | 1.2M | 686.78K | 8.64M | 4.2M | 5.92M | 9.72M | 4.17M | 2.4M | 2.54M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.06M | 799.94K | 1.45M | 1.77M | 1.46M | 773.82K | 722K | 947K | 731K | 947K |
| Days Sales Outstanding | 66.8 | 52.47 | 102.09 | 96.31 | 73.77 | 14.97 | 49.36 | 63.83 | 50.24 | 84.97 |
| Inventory | 1.73M | 2.18M | 2.15M | 2.85M | 3.21M | 2.42M | 2.06M | 2.38M | 1.49M | 1.52M |
| Days Inventory Outstanding | 167.41 | 208.74 | 200.87 | 211.89 | 171.26 | 55.48 | 153.37 | 180.52 | 113 | 133.19 |
| Other Current Assets | 195.76K | 300.41K | 202.4K | 0 | 0 | 447 | 0 | 0 | 255K | 0 |
| Total Non-Current Assets | 807.64K | 738.55K | 750.43K | 2.49M | 2.59M | 1.95M | 1.66M | 1.52M | 1.07M | 843K |
| Property, Plant & Equipment | 331.86K | 351.15K | 351.07K | 1.99M | 1.86M | 1.52M | 1.25M | 943K | 564K | 369K |
| Fixed Asset Turnover | 17.45x | 15.85x | 14.81x | 3.36x | 3.86x | 12.45x | 4.28x | 5.74x | 9.42x | 8.66x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 174.47K | 98.92K | 107.21K | 168.66K | 294.83K | 170K | 165K | 212K | 228K | 219K |
| Long-Term Investments | 165.32K | 165.32K | 165.32K | 165.32K | 165.32K | 165.32K | 165K | 165K | 165K | 660K |
| Other Non-Current Assets | 94.99K | 113.16K | 126.83K | 168.19K | 264.15K | 95.59K | 79K | 203K | 113K | 416K |
| Total Assets | 5.02M▲ 0% | 5.22M▲ 4.1% | 5.25M▲ 0.4% | 17.26M▲ 229.1% | 11.82M▼ 31.5% | 11.37M▼ 3.8% | 14.45M▲ 27.1% | 9.25M▼ 36.0% | 5.95M▼ 35.8% | 6.03M▲ 0% |
| Asset Turnover | 1.15x | 1.07x | 0.99x | 0.39x | 0.61x | 1.66x | 0.37x | 0.59x | 0.89x | 0.68x |
| Asset Growth % | -12.37% | 4.08% | 0.44% | 229.05% | -31.52% | -3.76% | 27.08% | -35.98% | -35.76% | -94.39% |
| Total Current Liabilities | 528.87K | 896.81K | 1.26M | 1.48M | 1.3M | 2.01M | 1.95M | 2.2M | 1.74M | 1.6M |
| Accounts Payable | 336.43K | 655.6K | 999.59K | 833.41K | 431K | 736K | 344K | 288K | 295K | 740K |
| Days Payables Outstanding | 32.57 | 62.81 | 93.34 | 61.94 | 23.02 | 16.9 | 25.66 | 21.88 | 22.37 | 50.92 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 284K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 51K | 60K | 85K | 55K | 194K |
| Other Current Liabilities | 15.57K | 31.36K | 37.97K | 0 | 389.28K | 282 | 0 | 655K | 655K | 0 |
| Current Ratio | 7.96x | 5.00x | 3.56x | 10.00x | 7.10x | 4.69x | 6.58x | 3.51x | 2.80x | 2.80x |
| Quick Ratio | 4.69x | 2.57x | 1.85x | 8.07x | 4.63x | 3.49x | 5.52x | 2.43x | 1.95x | 1.95x |
| Cash Conversion Cycle | 201.64 | 198.4 | 209.62 | 246.25 | 222.01 | 53.55 | 177.07 | 222.48 | 140.86 | 167.24 |
| Total Non-Current Liabilities | 8K | 0 | 999.59K | 1.57M | 1.29M | 1.04M | 785K | 459K | 100K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 1.57M | 1.29M | 1.04M | 785K | 459K | 100K | 299K |
| Deferred Tax Liabilities | 8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -8K | 0 | 0 | 0 | 0 | 284 | 0 | 0 | 0 | 0 |
| Total Liabilities | 528.87K | 896.81K | 1.26M | 3.05M | 2.59M | 3.05M | 2.73M | 2.66M | 1.84M | 1.6M |
| Total Debt | 0 | 0 | 0 | 1.78M | 1.62M | 1.38M | 1.08M | 785K | 458K | 284K |
| Net Debt | -1.23M | -1.2M | -686.78K | -6.86M | -2.58M | -4.54M | -8.64M | -3.38M | -1.94M | -2.26M |
| Debt / Equity | - | - | - | 0.13x | 0.18x | 0.17x | 0.09x | 0.12x | 0.11x | 0.11x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.06x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.47x |
| Interest Coverage | -3385.22x | -40047.43x | -51335.96x | -266983.11x | -20435.13x | - | - | - | - | - |
| Total Equity | 4.49M▲ 0% | 4.33M▼ 3.6% | 3.98M▼ 8.0% | 14.21M▲ 257.0% | 9.23M▼ 35.1% | 8.32M▼ 9.8% | 11.72M▲ 40.8% | 6.59M▼ 43.8% | 4.11M▼ 37.7% | 4.43M▲ 0% |
| Equity Growth % | -14.01% | -3.64% | -7.97% | 257.02% | -35.08% | -9.78% | 40.83% | -43.78% | -37.72% | -83.69% |
| Book Value per Share | 0.54 | 0.50 | 0.43 | 1.40 | 0.77 | 0.66 | 0.83 | 0.39 | 1.79 | 1.53 |
| Total Shareholders' Equity | 4.49M | 4.33M | 3.98M | 14.21M | 9.23M | 8.32M | 11.72M | 6.59M | 4.11M | 4.43M |
| Common Stock | 680.89K | 711.04K | 774.17K | 939.21K | 984.57K | 1.03M | 1.35M | 1.35M | 203K | 236K |
| Retained Earnings | -15.73M | -17.19M | -19.59M | -21.93M | -30.55M | -35.08M | -42.22M | -48.2M | -53.17M | -54.49M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -15.83K | -26.14K | -36.53K | -39.84K | -47.96K | -73.94K | -110K | -102K | -105K | -103K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BMRA Cash Flow Statement
Biomerica, Inc. (BMRA) cash flow — operating, investing & free cash flow history
| Line item | May'17 | May'18 | May'19 | May'20 | May'21 | May'22 | May'23 | May'24 | May'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -722.86K | -1.17M | -2.24M | -4.3M | -5.25M | -480.53K | -5.47M | -5.36M | -3.84M | -3.84M |
| Operating CF Margin % | -12.48% | -21.1% | -43.15% | -64.21% | -72.95% | -2.55% | -102.53% | -99% | -72.32% | - |
| Operating CF Growth % | -246.23% | -62.44% | -91.11% | -91.51% | -22.2% | 90.85% | -1039.15% | 2.06% | 28.35% | 133.44% |
| Net Income | -908.56K | -1.47M | -2.39M | -2.34M | -7.45M | -4.53M | -7.14M | -5.98M | -4.97M | -4.03M |
| Depreciation & Amortization | 219.22K | 186.6K | 162.91K | 398.63K | 375.86K | 594.82K | 351K | 374K | 400K | 408K |
| Stock-Based Compensation | 21.73K | 18.47K | 151.22K | 200.47K | 0 | 1.26M | 1.19M | 837K | 460K | 478K |
| Deferred Taxes | -16.5K | 31K | 10K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 8.07K | 23.4K | 12.91K | -37.97K | 3.67M | -719.15K | 168K | 31K | 4K | 27K |
| Working Capital Changes | -46.81K | 32.14K | -188.02K | -2.54M | -1.85M | 2.91M | -38K | -625K | 268K | 147K |
| Change in Receivables | -132.26K | 252.5K | -670.13K | -309.09K | -455.61K | 1.37M | -291K | -215K | 209K | 311K |
| Change in Inventory | 150.47K | -457.27K | 21.39K | -717.46K | -1.91M | 1.56M | 534K | -115K | 882K | 299K |
| Change in Payables | 10.45K | 319.17K | 343.99K | -12.88K | -403.33K | -403.33K | -80K | 246K | -466K | -106K |
| Cash from Investing | -96.08K | -130.35K | -171.11K | -118.93K | -295.58K | -170.34K | -78K | -115K | -37K | 0 |
| Capital Expenditures | -96.08K | -130.35K | -171.11K | -118.93K | -295.58K | -170.34K | -78K | -51K | -37K | 0 |
| CapEx % of Revenue | 1.66% | 2.34% | 3.29% | 1.78% | 4.11% | 0.9% | 1.46% | 0.94% | 0.7% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -64K | 0 | 0 |
| Cash from Financing | 157.73K | 1.29M | 1.91M | 12.37M | 1.11M | 2.39M | 9.39M | -81K | 2.11M | 3.13M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -81K | 1000K | 2.48M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -165.92K | -85K | -705K | 0 | 0 | -19K |
| Other Financing | 0 | 27.44K | 130.85K | 223.53K | 102.25K | 77.52K | 81K | 0 | -32K | -100K |
| Net Change in Cash | -663.46K▲ 0% | -20.56K▲ 96.9% | -518.12K▼ 2420.2% | 7.95M▲ 1635.2% | -4.44M▼ 155.8% | 1.72M▲ 138.7% | 3.8M▲ 121.3% | -5.55M▼ 245.9% | -1.77M▲ 68.1% | 172K▲ 0% |
| Free Cash Flow | -818.94K▲ 0% | -1.3M▼ 59.3% | -2.42M▼ 85.1% | -4.42M▼ 82.9% | -5.55M▼ 25.6% | -650.87K▲ 88.3% | -5.55M▼ 753.0% | -5.48M▲ 1.4% | -3.88M▲ 29.2% | -2.93M▲ 0% |
| FCF Margin % | -14.14% | -23.45% | -46.44% | -65.99% | -77.06% | -3.45% | -103.99% | -101.13% | -73.02% | -65.68% |
| FCF Growth % | -169.41% | -59.3% | -85.13% | -82.86% | -25.61% | 88.27% | -753.01% | 1.37% | 29.18% | 41.67% |
| FCF per Share | -0.10 | -0.15 | -0.26 | -0.43 | -0.47 | -0.05 | -0.39 | -0.33 | -1.69 | -1.69 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.80x | 0.94x | 1.84x | 0.71x | 0.11x | 0.77x | 0.90x | 0.77x | 0.73x |
| Interest Paid | 282 | 37 | 47 | 9 | 367 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 800 | 800 | 14.24K | 7.39K | 27.17K | 24K | 51K | 41K | 10K | 13K |
BMRA Key Ratios
Biomerica, Inc. (BMRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -18.71% | -33.26% | -57.62% | -25.71% | -63.53% | -51.63% | -71.23% | -65.28% | -92.99% | -90.76% |
| Return on Invested Capital (ROIC) | -21.71% | -34.81% | -56.42% | -33.85% | -80.35% | -65.18% | -157.61% | -151.76% | -143.49% | -143.49% |
| Gross Margin | 34.91% | 31.53% | 24.84% | 26.62% | 5.09% | 15.78% | 8.35% | 11.28% | 9.38% | 5.61% |
| Net Margin | -15.69% | -26.34% | -46.01% | -34.95% | -103.43% | -24.01% | -133.73% | -110.4% | -93.64% | -90.29% |
| Debt / Equity | - | - | - | 0.13x | 0.18x | 0.17x | 0.09x | 0.12x | 0.11x | 0.11x |
| Interest Coverage | -3385.22x | -40047.43x | -51335.96x | -266983.11x | -20435.13x | - | - | - | - | - |
| FCF Conversion | 0.80x | 0.80x | 0.94x | 1.84x | 0.71x | 0.11x | 0.77x | 0.90x | 0.77x | 0.73x |
| Revenue Growth | 12.68% | -3.93% | -6.53% | 28.69% | 7.57% | 162.14% | -71.71% | 1.42% | -1.92% | -20.05% |
BMRA Frequently Asked Questions
Biomerica, Inc. (BMRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Biomerica, Inc. (BMRA) reported $4.5M in revenue for fiscal year 2025. This represents a 53% decrease from $9.5M in 1996.
Biomerica, Inc. (BMRA) saw revenue decline by 1.9% over the past year.
Biomerica, Inc. (BMRA) reported a net loss of $4.0M for fiscal year 2025.
Dividend & Returns
Biomerica, Inc. (BMRA) has a return on equity (ROE) of -93.0%. Negative ROE indicates the company is unprofitable.
Biomerica, Inc. (BMRA) had negative free cash flow of $2.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More BMRA
Biomerica, Inc. (BMRA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates